BioMarin Pharmaceutical Inc. (BMRN)

74.95
NASDAQ : Health Technology
Prev Close 76.00
Day Low/High 74.42 / 77.11
52 Wk Low/High 70.82 / 106.74
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 179.46M
Market Cap 13.64B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

BioMarin Announces Second Quarter 2019 Financial Results

BioMarin Announces Second Quarter 2019 Financial Results

- Total Revenues of $387.8 million in the Quarter

BioMarin To Host Second Quarter 2019 Financial Results Conference Call And Webcast On Thursday, August 1 At 4:30pm ET

BioMarin To Host Second Quarter 2019 Financial Results Conference Call And Webcast On Thursday, August 1 At 4:30pm ET

SAN RAFAEL, Calif., July 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Appoints Pharmaceutical Veteran And Former J & J Executive, Liz McKee Anderson, To Board Of Directors

BioMarin Appoints Pharmaceutical Veteran And Former J & J Executive, Liz McKee Anderson, To Board Of Directors

SAN RAFAEL, Calif., July 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.

BioMarin Plans Regulatory Submissions For Marketing Authorization Of Valoctocogene Roxaparvovec To Treat Severe Hemophilia A In 4Q 2019 In Both U.S. And Europe

BioMarin Plans Regulatory Submissions For Marketing Authorization Of Valoctocogene Roxaparvovec To Treat Severe Hemophilia A In 4Q 2019 In Both U.S. And Europe

Potential 1st Marketing Application for a Gene Therapy Product in Any Type of Hemophilia to be Reviewed by Health Authorities

BioMarin Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis (ISTH) 2019 Congress In Melbourne, Australia From July 6-10, 2019

BioMarin Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis (ISTH) 2019 Congress In Melbourne, Australia From July 6-10, 2019

Abstract Covers Efficacy and Safety of AAV Gene Therapy Over 3 Years with Valoctocogene Roxaparvovec in Severe Hemophilia A

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

BioMarin Announces New England Journal Of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia

BioMarin Announces New England Journal Of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia

Company Announces Enrollment Met for 2-5 Year-Old Cohort in Separate Phase 2 Study in Infants and Young Children

BioMarin To Participate In Goldman Sachs 40th Annual Global Healthcare Conference On Tuesday, June 11 In Rancho Palos Verdes, CA

BioMarin To Participate In Goldman Sachs 40th Annual Global Healthcare Conference On Tuesday, June 11 In Rancho Palos Verdes, CA

SAN RAFAEL, Calif., June 5, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Announces Approval Of Vimizim® (elosulfase Alfa) In China For Treatment Of Morquio A Syndrome

BioMarin Announces Approval Of Vimizim® (elosulfase Alfa) In China For Treatment Of Morquio A Syndrome

First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition

BioMarin Provides 3 Years Of Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A

BioMarin Provides 3 Years Of Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A

Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)

BioMarin To Host Conference Call Tuesday, May 28, 2019 To Provide A Valoctocogene Roxaparvovec Phase 2 And Phase 3 Update

BioMarin To Host Conference Call Tuesday, May 28, 2019 To Provide A Valoctocogene Roxaparvovec Phase 2 And Phase 3 Update

SAN RAFAEL, Calif., May 27, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin To Participate In 2019 RBC Capital Markets Global Healthcare Conference On May 21 In New York City

BioMarin To Participate In 2019 RBC Capital Markets Global Healthcare Conference On May 21 In New York City

SAN RAFAEL, Calif., May 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

2 Stocks You Definitely Should Consider Shorting This Week

2 Stocks You Definitely Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

A Big Biotech, an Online Apparel Retailer and Other Stocks That Look Good Short

BMRN, SFIX, INGR, VC and IQV all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGTC, DCO, HAE, LILA, LILAK, NRT, RCII Downgrades: ANDE, BMRN, CCO, CLH, HCP, HGV, HIIQ, INGR, NCMI, NHTC Initiations: FEDU Read on to get TheStreet Quant Ratings' detailed report:

Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs

Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs

I am incrementally using buy-write option orders to add some shares to core holdings.

BioMarin To Participate In Bank Of America Merrill Lynch Health Care Conference On May 15 In Las Vegas

BioMarin To Participate In Bank Of America Merrill Lynch Health Care Conference On May 15 In Las Vegas

SAN RAFAEL, Calif., May 8, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

European Commission Approves Palynziq® (pegvaliase Injection) For Treatment Of Phenylketonuria (PKU) In Patients Aged 16 Years Or Older

European Commission Approves Palynziq® (pegvaliase Injection) For Treatment Of Phenylketonuria (PKU) In Patients Aged 16 Years Or Older

First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg

BioMarin Announces First Quarter 2019 Financial Results

BioMarin Announces First Quarter 2019 Financial Results

- Total Revenues Top $400 million in the Quarter

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Forbes Names BioMarin 4th Best Midsize Employer In America

Forbes Names BioMarin 4th Best Midsize Employer In America

Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' Industry

BioMarin To Host First Quarter 2019 Financial Results Conference Call And Webcast On Thursday, April 25 At 4:30pm ET

BioMarin To Host First Quarter 2019 Financial Results Conference Call And Webcast On Thursday, April 25 At 4:30pm ET

SAN RAFAEL, Calif., April 2, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Becomes #3 Most Shorted Nasdaq 100 Component, Replacing Fiserv

BioMarin Pharmaceutical Becomes #3 Most Shorted Nasdaq 100 Component, Replacing Fiserv

The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

TheStreet Quant Rating: D+ (Sell)